Immune Effective Score as a Predictor of Response to Neoadjuvant Trastuzumab Therapy and a Prognostic Indicator for HER2-Positive Breast Cancer
Background: HER2-positive breast cancer (BC) is a highly aggressive phenotype. The role of the host immune features in predictive response to anti-HER2 therapies and prognosis in BC has already been suggested. We aimed to develop a predictive and prognostic model and examine its relevance to the cli...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-01-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/29/1/26 |
| _version_ | 1797494895090335744 |
|---|---|
| author | Xueying Wu Chenyang Zhang Henghui Zhang |
| author_facet | Xueying Wu Chenyang Zhang Henghui Zhang |
| author_sort | Xueying Wu |
| collection | DOAJ |
| description | Background: HER2-positive breast cancer (BC) is a highly aggressive phenotype. The role of the host immune features in predictive response to anti-HER2 therapies and prognosis in BC has already been suggested. We aimed to develop a predictive and prognostic model and examine its relevance to the clinical outcomes of patients with HER2-positive BC. Methods: Immune effective score (IES) was constructed using principal component analysis algorithms. A bioinformatic analysis using four independent cohorts (GSE66305, <i>n</i> = 88; GSE130786, <i>n</i> = 110; TCGA, <i>n</i> = 123; METABRIC, <i>n</i> = 236) established associations between IES and clinical outcomes. Results: Genes associated with neoadjuvant trastuzumab therapy response were enriched in pathways related to antitumor immune activities. IES was demonstrated to be a predictive biomarker to neoadjuvant trastuzumab therapy benefits (GSE66305: area under the curve (AUC) = 0.804; GSE130786: AUC = 0.704). In addition, IES was identified as an independent prognostic factor for overall survival (OS) in the TCGA cohort (<i>p</i> = 0.036, hazard ratio (HR): 0.66, 95% confidence interval (CI): 0.449–0.97) and METABRIC cohort (<i>p</i> = 0.037, HR: 0.9, 95% CI: 0.81–0.99). Conclusion: IES has a predictive value for response to neoadjuvant trastuzumab therapy and independent prognostic value for HER2-positive breast cancer. |
| first_indexed | 2024-03-10T01:40:48Z |
| format | Article |
| id | doaj.art-d8f6de30bfb142139db5c1619832602b |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-03-10T01:40:48Z |
| publishDate | 2022-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-d8f6de30bfb142139db5c1619832602b2023-11-23T13:26:02ZengMDPI AGCurrent Oncology1198-00521718-77292022-01-0129128329310.3390/curroncol29010026Immune Effective Score as a Predictor of Response to Neoadjuvant Trastuzumab Therapy and a Prognostic Indicator for HER2-Positive Breast CancerXueying Wu0Chenyang Zhang1Henghui Zhang2Institute of Molecular Medicine, Peking University, Beijing 100871, ChinaInstitute of Molecular Medicine, Peking University, Beijing 100871, ChinaBiomedical Innovation Center, Beijing Shijitan Hospital, School of Oncology, Capital Medical University, Beijing 100038, ChinaBackground: HER2-positive breast cancer (BC) is a highly aggressive phenotype. The role of the host immune features in predictive response to anti-HER2 therapies and prognosis in BC has already been suggested. We aimed to develop a predictive and prognostic model and examine its relevance to the clinical outcomes of patients with HER2-positive BC. Methods: Immune effective score (IES) was constructed using principal component analysis algorithms. A bioinformatic analysis using four independent cohorts (GSE66305, <i>n</i> = 88; GSE130786, <i>n</i> = 110; TCGA, <i>n</i> = 123; METABRIC, <i>n</i> = 236) established associations between IES and clinical outcomes. Results: Genes associated with neoadjuvant trastuzumab therapy response were enriched in pathways related to antitumor immune activities. IES was demonstrated to be a predictive biomarker to neoadjuvant trastuzumab therapy benefits (GSE66305: area under the curve (AUC) = 0.804; GSE130786: AUC = 0.704). In addition, IES was identified as an independent prognostic factor for overall survival (OS) in the TCGA cohort (<i>p</i> = 0.036, hazard ratio (HR): 0.66, 95% confidence interval (CI): 0.449–0.97) and METABRIC cohort (<i>p</i> = 0.037, HR: 0.9, 95% CI: 0.81–0.99). Conclusion: IES has a predictive value for response to neoadjuvant trastuzumab therapy and independent prognostic value for HER2-positive breast cancer.https://www.mdpi.com/1718-7729/29/1/26HER2-positive breast cancerneoadjuvanttrastuzumabpathological complete responseprognosis |
| spellingShingle | Xueying Wu Chenyang Zhang Henghui Zhang Immune Effective Score as a Predictor of Response to Neoadjuvant Trastuzumab Therapy and a Prognostic Indicator for HER2-Positive Breast Cancer Current Oncology HER2-positive breast cancer neoadjuvant trastuzumab pathological complete response prognosis |
| title | Immune Effective Score as a Predictor of Response to Neoadjuvant Trastuzumab Therapy and a Prognostic Indicator for HER2-Positive Breast Cancer |
| title_full | Immune Effective Score as a Predictor of Response to Neoadjuvant Trastuzumab Therapy and a Prognostic Indicator for HER2-Positive Breast Cancer |
| title_fullStr | Immune Effective Score as a Predictor of Response to Neoadjuvant Trastuzumab Therapy and a Prognostic Indicator for HER2-Positive Breast Cancer |
| title_full_unstemmed | Immune Effective Score as a Predictor of Response to Neoadjuvant Trastuzumab Therapy and a Prognostic Indicator for HER2-Positive Breast Cancer |
| title_short | Immune Effective Score as a Predictor of Response to Neoadjuvant Trastuzumab Therapy and a Prognostic Indicator for HER2-Positive Breast Cancer |
| title_sort | immune effective score as a predictor of response to neoadjuvant trastuzumab therapy and a prognostic indicator for her2 positive breast cancer |
| topic | HER2-positive breast cancer neoadjuvant trastuzumab pathological complete response prognosis |
| url | https://www.mdpi.com/1718-7729/29/1/26 |
| work_keys_str_mv | AT xueyingwu immuneeffectivescoreasapredictorofresponsetoneoadjuvanttrastuzumabtherapyandaprognosticindicatorforher2positivebreastcancer AT chenyangzhang immuneeffectivescoreasapredictorofresponsetoneoadjuvanttrastuzumabtherapyandaprognosticindicatorforher2positivebreastcancer AT henghuizhang immuneeffectivescoreasapredictorofresponsetoneoadjuvanttrastuzumabtherapyandaprognosticindicatorforher2positivebreastcancer |